Xanomeline/trospium clinical trials

A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

This study is looking at how a new medicine, Xanomeline/Trospium (XT), affects thinking and memory in adults with schizophrenia over one year. XT is already approved for treating other symptoms but this study focuses on cognitive benefits.